We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Benchmark Holdings Plc | LSE:BMK | London | Ordinary Share | GB00BGHPT808 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.50 | -1.71% | 28.70 | 7,166 | 16:35:27 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 28.50 | 28.90 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 147.73M | -39.46M | -0.0533 | -5.48 | 216.18M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:18:54 | O | 12 | 28.512 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 07/1/2025 | 07:00 | UK RNS | Benchmark Holdings PLC Publication of Annual Report |
| 31/12/2024 | 07:00 | UK RNS | Benchmark Holdings PLC Total Voting Rights |
| 16/12/2024 | 13:00 | UK RNS | Benchmark Holdings PLC Result of General Meeting |
| 12/12/2024 | 11:10 | ALNC |  Benchmark Holdings annual loss widens; sets returns from Genetics sale |
| 12/12/2024 | 07:01 | UK RNS | Benchmark Holdings PLC Chairman Appointment |
| 12/12/2024 | 07:00 | UK RNS | Benchmark Holdings PLC Full Year Results |
| 29/11/2024 | 11:30 | UK RNS | Benchmark Holdings PLC Total Voting Rights |
| 27/11/2024 | 09:12 | UK RNS | Numis Securities Limited Form 8.5 (EPT/RI) - Benchmark Holdings plc |
| 26/11/2024 | 15:00 | UK RNS | Benchmark Holdings PLC Notice of GM |
| 26/11/2024 | 11:15 | UK RNS | Janus Henderson Investors Form 8.3 - Benchmark Holdings plc |
Benchmark (BMK) Share Charts1 Year Benchmark Chart |
|
1 Month Benchmark Chart |
Intraday Benchmark Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/1/2025 | 12:32 | Benchmark Holdings Plc | 524 |
| 19/5/2021 | 07:35 | SALMON prices 30 year high and CAT VACCINES are Go-Go | 566 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-01-30 16:18:56 | 28.51 | 12 | 3.42 | O |
| 2025-01-30 14:20:11 | 28.65 | 2,000 | 572.90 | O |
| 2025-01-30 14:20:10 | 28.65 | 2,000 | 572.90 | O |
| 2025-01-30 14:05:03 | 28.65 | 1,500 | 429.68 | O |
| 2025-01-30 14:05:02 | 28.65 | 1,500 | 429.68 | O |
| Top Posts |
|---|
Posted at 30/1/2025 08:20 by Benchmark Daily Update Benchmark Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 29.20p.Benchmark currently has 740,336,243 shares in issue. The market capitalisation of Benchmark is £216,178,183. Benchmark has a price to earnings ratio (PE ratio) of -5.48. This morning BMK shares opened at - |
Posted at 10/1/2025 14:21 by controlledmadness Put in money terms the equity prediction is about 17p being returned per share in 2025.Is the market saying that the share price has taken this into account or that the resulting company after the 17 p return mat have a 10p a share value? |
Posted at 10/1/2025 10:35 by edmonda "FY24 results: refocus post disposal" - new research (link below)Benchmark Holdings reported FY24 revenue from continuing operations of £90.4m, -13%YoY (currency adjusted, CER, -6%YoY), and (adj.) EBITDA of £11.9m, -30%YoY (CER: -24%YoY reflecting the decline in revenue in the Health business (-57%YoY) and changes in Advanced Nutrition product mix. Net debt was reduced from £65.5m in FY23 to £49.0m due to the impact of the discontinued Genetics business removing debt related to the Saltern facility. The focus is now on the structure of operations post sale of the Genetics business area, streamlining the organisation and reducing costs. Post-divestment our revenue and (adj.) EBITDA outlook is determined principally by two factors: trends in the overall market for shrimp (demand and prices), and contribution from the Health business based on Salmosan®Vet revenue streams, in FY25 respectively £86.7m and £12.7m, and for FY26, £90.9m and £14.0m. We reinstate our fair value at 43p/share, to be reviewed on completion of the disposal process as details of the use of proceeds, structure of the balance sheet and proposals for further restructuring emerge. Our revised Fair Value, based on a 5-year DCF, is inclusive of a return of capital to shareholders which we estimate at £158m, to be paid in FY25 (£128m) and FY27 (£30m). Link to note: |
Posted at 10/1/2025 10:18 by jaf111 Can anyone help explain recent weakness in share price….is there a problem with the Novo sale?Market cap approx £200m which is substantially below the £260m due from Genetics sale. Clearly I must be missing something….. |
Posted at 07/8/2024 12:33 by edmonda Save the Date! 22nd August - Q3 Results Investor Presentation - sign up below!Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, will be conducting an investor presentation following publication of their Q3 results for the nine month period ended 30 June 2024. The online event will be hosted by Trond Williksen, CEO, and Septima Maguire, CFO, and will take place on Thursday 22nd August at 12.00pm (UK time). The webinar is open to all existing and potential shareholders. Questions can be submitted during the presentation to be addressed at the end. Link to register here: |
Posted at 05/12/2023 20:27 by newbold120 I suspect it's worth more than that Ed. JNE is the price setter? Interesting he has joined the board |
Posted at 01/12/2023 12:42 by edmonda "FY23 results: consolidation and cash generation" (new report now available)Link to note: For the year to 30 September 2023, Benchmark Holdings reported revenue FY23 of £169.6m, +7.5%YoY (currency adjusted +7%YoY) which was 0.7% below our outlook, and adjusted EBITDA of £35.5m, +9%YoY, 5% above our outlook. Net operating cash of £20.0m was almost double FY22 (£10.8m) with a notable improvement in working capital management from £(12.0)m to £(1.0)m underlining efforts to control costs and improve operational efficiency. Net debt was £45.6m, with year-end cash at £36.5m. The Group reports Genetics operations at normalised levels, early signs of a recovery in shrimp markets positive for Advanced Nutrition, and in the Health segment improved Q1 24 demand visibility with Clean Treat® at improved capacity utilisation. Most significantly, in FY23 the Group exhibited discipline in cost and cash management which establishes a sound platform for growth in FY24. We revise down our FY24 revenue outlook by -6% and for FY25 by -7% principally due to a 24% reduction in the outlook for Health. For (adj.) EBITDA the adjustments are -4% in FY24 but +3% in FY25, indicative of continued improvements expected in operational efficiency. We maintain our fair value at 63p/share. |
Posted at 29/8/2023 08:44 by edmonda New note and Investor Presentation recording (see full details below)For the three months to 30th June 2023, Benchmark Holdings reported revenue of £34.3m, -5.5%YoY (currency-adjusted -1%YoY), as 10%YoY growth in Genetics (42% of total) was offset by the impact of reduced demand in global shrimp markets, resulting in a 17%YoY decline in Advanced Nutrition revenues (47% of total). Adjusted EBITDA1 declined 23%YoY (£5.1m), a 14.8% margin (Q3 22: 18.1%); on a currency-adjusted basis -13%YoY. Net operating cash inflow of £1.7m contrasted with £(1.0)m outflow in Q3 22, with net debt of £45.7m (FY22: £59.3m) and healthy cash reserves of £32.9m. Q3 under-performance in the Advanced Nutrition business area indicates a revision to our full year FY23 outlook and the basis for FY24 estimates; a 7.2% reduction in our FY23 (adj.) EBITDA outlook and -7.2% for FY24. We maintain our fair value at 63p/share, backed by sound cashflow management, confidence in Genetics salmon eggs demand and production capacity and prospects for Benchmark’s Ectosan®Vet and Clean Treat® treatments. Link to research report: |
Posted at 24/5/2023 14:39 by murdo mcsponge In the light of the Q figs released, what on earth justifies a 5% drop in the Stock's price, and the sale of over 7 million shares? I presume the sales are by AIM holders which would go to prove that UK investors just don't understand The Company and its products and services, and their position in what might be called a "Sunrise" Industry. No wonder The Board decided to focus on The Oslo Exchange. The Norwegians really understand Aquaculture, and have made fortunes out of it. |
Posted at 26/4/2023 14:55 by belfast_child Maybe we will see BMK move into profit next quarter? Fingers crossed. |
Posted at 23/3/2022 20:51 by hedgehog 100 It's interesting to note BMK's strong cash position:"Cash of £50.6m and Liquidity (cash and available facility) of £61.6m as at 21 February 2022" Considering the buy-&-build strategy employed by BMK, then OTAQ, which has BMK founder Malcolm Pye as a director, could be a potential BMK takeover target. In fact, at its current share price of just 20.5p OTAQ looks a sitting duck for a BMK takeover attempt, and looks a prefect fit. Thought I think that it would have to pay at least double or treble OTAQ's current share price to succeed. "Malcolm Pye Non Executive Director Malcolm founded, and from 1999 to 2019 was Chief Executive of, Benchmark Holdings plc ("Benchmark"), the world's leading aquaculture health, nutrition and genetics business. Malcolm has over 35 years' experience in international agribusiness through his various roles at Hillsdown Holdings (then HMTF Group), and through building Benchmark from the initial start-up into a major international aquaculture technology business serving the global salmon, shrimp, tilapia and farmed fish industries. Malcolm focused Benchmark's activities on animal health, breeding and genetics, advanced nutrition and knowledge/technology delivery and led the flotation of Benchmark in 2013, maintaining a lead role in investor engagement." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
